查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1573078

水痘天疱疮市场：按药物类别、给药途径、最终用户、年龄层、治疗类型、严重程度、诊断测试 - 2025-2030 年全球预测

Bullous pemphigoid Market by Drug Class (Biologics, Corticosteroids, Immunosuppressants), Route Of Administration (Intravenous, Oral, Topical), End-User, Age Group, Treatment Type, Severity, Diagnosis Test - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，水痘天疱疮市场价值为3.4528亿美元，预计到2024年将达到3.5838亿美元，复合年增长率为5.60%，到2030年将达到5.0568亿美元。

水痘天疱疮是一种罕见的自体免疫皮肤病，其特征是充满液体的大水痘，主要影响老年人。治疗这种疾病的疗法和产品市场包括皮质类固醇、免疫抑制剂和新型生物製药等处方药，以及用于症状管理的非处方护肤品。人口老化的加剧以及对更安全、更有效、副作用更少的治疗方法的需求支持了开拓这个市场的需求。主要最终用户包括皮肤科医生、医院和专科诊所，其中重点关注医疗保健提供者。当前的市场成长是由生物治疗方法的进步、自体免疫疾病意识的提高以及医疗保健支出的增加所推动的。标靶治疗的发展是目前主要的成长催化剂，为製药公司考虑个人化医疗方法提供了重要机会。然而，生物製药的高成本、由于疾病罕见而导致的患者群体有限以及潜在的监管障碍等挑战可能会抑製成长。解决这些限制需要继续探索具有成本效益的治疗方法，并开发新型药物输送系统，以提高患者的依从性和治疗结果。生物相似药和针对患者的治疗方案代表了一个创新领域，可以提供经济效益和客製化治疗。此外，製药公司和研究机构之间的伙伴关係有可能加速新疗法的发现并加速临床试验过程。希望从这个市场中获利的公司应该投资于提高其研发能力并建立合作伙伴关係，使他们能够有效地与监管机构打交道。由于市场的研究主导和高度监管的性质，持续关注新兴研究趋势和以患者为中心的解决方案对于持续的业务成长和扩张至关重要。

主要市场统计
基准年[2023] 3.4528亿美元
预测年份 [2024] 3.5838亿美元
预测年份 [2030] 50568万美元
复合年增长率（%） 5.60%

市场动态：快速发展的水痘天疱疮市场的关键市场洞察

供需的动态交互作用正在改变水痘天疱疮市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 医疗费用的增加和政府的支持政策改善了水痘天疱疮治疗的机会
    • 扩大新兴国家的医疗保健基础设施以促进市场渗透和成长
    • 水痘天疱疮治疗临床试验数量增加，提高市场竞争力
  • 市场限制因素
    • 缺乏专门治疗水痘类天疱疮的医疗专业人员影响了市场成长
  • 市场机会
    • 引入先进的诊断工具以改善水痘天疱疮的早期检测
    • 水痘天疱疮药企与研究机构策略联盟
  • 市场挑战
    • 用于水痘天疱疮市场早期检测的先进诊断工具的可用性有限

波特的五力：驾驭水痘天疱疮市场的策略工具

波特的五力框架是了解水痘天疱疮市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解水痘天疱疮市场的外部影响

外部宏观环境因素在塑造水痘天疱疮市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解水痘类天疱疮市场的竞争格局

水痘天疱疮市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵水痘天疱疮市场供应商的绩效评估

FPNV定位矩阵是评估水痘天疱疮市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了水痘天疱疮市场的成功之路

对于希望加强其在全球市场的影响力的公司来说，对水痘天疱疮市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 医疗保健成本增加和政府支持政策增加了获得水痘天疱疮治疗的机会
      • 新兴国家医疗保健基础设施的扩张推动市场渗透和成长
      • 水痘天疱疮治疗方法临床试验数量增加提高市场竞争力
    • 抑制因素
      • 缺乏专门治疗水痘类天疱疮的医疗专业人员影响了市场成长
    • 机会
      • 实施先进的诊断工具以改善水痘天疱疮的早期发现
      • 药厂与研究机构策略伙伴关係水痘天疱疮
    • 任务
      • 大疱性类水痘市场用于早期检测的先进诊断工具的可用性有限
  • 市场区隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 大疱性类水痘市场：依药物类别

  • 生物製药
    • Rituximab
  • 皮质类固醇
    • 全身性皮质类固醇
    • 局部皮质类固醇
  • 免疫抑制剂
    • Azathioprine
    • 胺基甲基叶酸
    • Mycophenolate Mofetil

第七章 大疱性类水痘市场：依给药途径

  • 静脉
  • 口服
  • 局部的

第 8 章 大疱性类水痘市场：依最终使用者分类

  • 诊所
  • 居家护理
  • 医院
    • 私立医院
    • 公立医院

第 9 章 大疱性类水痘市场：依年龄组

  • 成人
  • 老年病
  • 小儿科

第 10 章 大疱性类水痘市场：依治疗类型

  • 一线治疗
  • 维持治疗
  • 二线治疗

第十一章 大疱性类水痘市场：依严重程度

  • 温和的
  • 适度
  • 严重

第十二章 大疱性类水痘市场：透过诊断测试

  • 切片检查
  • 直接萤光
  • 酵素连结免疫吸附试验
  • 间接萤光

第十三章北美与南美洲水痘天疱疮市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十四章亚太水痘天疱疮市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十五章欧洲、中东和非洲的水痘天疱疮市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十六章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • 1. AbbVie
  • 2. Alexion Pharmaceuticals
  • 3. Almirall
  • 4. Amgen
  • 5. AstraZeneca
  • 6. Biogen
  • 7. Bristol-Myers Squibb
  • 8. Dermira
  • 9. Eli Lilly and Company
  • 10. F. Hoffmann-La Roche
  • 11. GlaxoSmithKline
  • 12. Horizon Therapeutics
  • 13. Johnson & Johnson
  • 14. Merck & Co.
  • 15. Novartis
  • 16. Pfizer
  • 17. Regeneron Pharmaceuticals
  • 18. Sanofi
  • 19. Takeda Pharmaceutical Company
  • 20. UCB SA
Product Code: MRR-535C62918796

The Bullous pemphigoid Market was valued at USD 345.28 million in 2023, expected to reach USD 358.38 million in 2024, and is projected to grow at a CAGR of 5.60%, to USD 505.68 million by 2030.

Bullous pemphigoid is a rare autoimmune skin disease characterized by large, fluid-filled blisters, primarily affecting the elderly. The market for therapies and products addressing this condition involves prescription drugs like corticosteroids, immunosuppressants, and novel biologics, as well as over-the-counter skincare products for symptom management. The necessity of developments in this market is underscored by an increasing aging population and the need for safer, more effective treatments with fewer side effects. Key end-users include dermatologists, hospitals, and specialty clinics, highlighting a significant focus on healthcare providers. Current market growth is propelled by advancements in biologic treatments, growing awareness about autoimmune diseases, and increased healthcare spending. The development of targeted therapies, which are currently a primary growth catalyst, provides substantial opportunities for pharmaceutical companies to consider personalized medicine approaches. However, challenges such as the high cost of biologics, limited patient populations due to the disease's rarity, and potential regulatory hurdles can impede growth. Addressing these limitations calls for continued research into cost-effective treatment options and leveraging novel drug delivery systems to enhance patient compliance and outcomes. There is a robust area for innovation in biosimilars and patient-specific treatment protocols, which could offer both economic advantages and customized care. Furthermore, partnerships between pharmaceutical companies and research institutions could facilitate the discovery of new therapeutics and expedite clinical testing processes. Businesses seeking to capitalize on this market should invest in growing their R&D capabilities and establishing alliances to navigate regulatory pathways effectively. As the market nature is research-driven and heavily regulated, maintaining a keen focus on emerging research trends and patient-centric solutions is crucial for sustained business growth and expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 345.28 million
Estimated Year [2024] USD 358.38 million
Forecast Year [2030] USD 505.68 million
CAGR (%) 5.60%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bullous pemphigoid Market

The Bullous pemphigoid Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising healthcare expenditure and supportive government policies enhancing access to bullous pemphigoid treatments
    • Expansion of healthcare infrastructure in emerging economies facilitating market penetration and growth
    • Growing number of clinical trials for bullous pemphigoid treatments increasing market competitiveness
  • Market Restraints
    • Lack of medical professionals specializing in bullous pemphigoid affecting market growth
  • Market Opportunities
    • Implementation of advanced diagnostic tools to improve early detection of bullous pemphigoid
    • Strategic partnerships between pharmaceutical companies and research institutes for bullous pemphigoid
  • Market Challenges
    • Limited availability of advanced diagnostic tools for early detection in bullous pemphigoid market

Porter's Five Forces: A Strategic Tool for Navigating the Bullous pemphigoid Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bullous pemphigoid Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bullous pemphigoid Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bullous pemphigoid Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bullous pemphigoid Market

A detailed market share analysis in the Bullous pemphigoid Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bullous pemphigoid Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bullous pemphigoid Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bullous pemphigoid Market

A strategic analysis of the Bullous pemphigoid Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bullous pemphigoid Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Alexion Pharmaceuticals, Almirall, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Dermira, Eli Lilly and Company, F. Hoffmann-La Roche, GlaxoSmithKline, Horizon Therapeutics, Johnson & Johnson, Merck & Co., Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi, Takeda Pharmaceutical Company, and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Bullous pemphigoid Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Biologics, Corticosteroids, and Immunosuppressants. The Biologics is further studied across Rituximab. The Corticosteroids is further studied across Systemic Corticosteroids and Topical Corticosteroids. The Immunosuppressants is further studied across Azathioprine, Methotrexate, and Mycophenolate Mofetil.
  • Based on Route Of Administration, market is studied across Intravenous, Oral, and Topical.
  • Based on End-User, market is studied across Clinics, Home Care, and Hospitals. The Hospitals is further studied across Private Hospitals and Public Hospitals.
  • Based on Age Group, market is studied across Adults, Geriatric, and Pediatric.
  • Based on Treatment Type, market is studied across First-Line Treatment, Maintenance Treatment, and Second-Line Treatment.
  • Based on Severity, market is studied across Mild, Moderate, and Severe.
  • Based on Diagnosis Test, market is studied across Biopsy, Direct Immunofluorescence, Elisa, and Indirect Immunofluorescence.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising healthcare expenditure and supportive government policies enhancing access to bullous pemphigoid treatments
      • 5.1.1.2. Expansion of healthcare infrastructure in emerging economies facilitating market penetration and growth
      • 5.1.1.3. Growing number of clinical trials for bullous pemphigoid treatments increasing market competitiveness
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of medical professionals specializing in bullous pemphigoid affecting market growth
    • 5.1.3. Opportunities
      • 5.1.3.1. Implementation of advanced diagnostic tools to improve early detection of bullous pemphigoid
      • 5.1.3.2. Strategic partnerships between pharmaceutical companies and research institutes for bullous pemphigoid
    • 5.1.4. Challenges
      • 5.1.4.1. Limited availability of advanced diagnostic tools for early detection in bullous pemphigoid market
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bullous pemphigoid Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Biologics
    • 6.2.1. Rituximab
  • 6.3. Corticosteroids
    • 6.3.1. Systemic Corticosteroids
    • 6.3.2. Topical Corticosteroids
  • 6.4. Immunosuppressants
    • 6.4.1. Azathioprine
    • 6.4.2. Methotrexate
    • 6.4.3. Mycophenolate Mofetil

7. Bullous pemphigoid Market, by Route Of Administration

  • 7.1. Introduction
  • 7.2. Intravenous
  • 7.3. Oral
  • 7.4. Topical

8. Bullous pemphigoid Market, by End-User

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Home Care
  • 8.4. Hospitals
    • 8.4.1. Private Hospitals
    • 8.4.2. Public Hospitals

9. Bullous pemphigoid Market, by Age Group

  • 9.1. Introduction
  • 9.2. Adults
  • 9.3. Geriatric
  • 9.4. Pediatric

10. Bullous pemphigoid Market, by Treatment Type

  • 10.1. Introduction
  • 10.2. First-Line Treatment
  • 10.3. Maintenance Treatment
  • 10.4. Second-Line Treatment

11. Bullous pemphigoid Market, by Severity

  • 11.1. Introduction
  • 11.2. Mild
  • 11.3. Moderate
  • 11.4. Severe

12. Bullous pemphigoid Market, by Diagnosis Test

  • 12.1. Introduction
  • 12.2. Biopsy
  • 12.3. Direct Immunofluorescence
  • 12.4. Elisa
  • 12.5. Indirect Immunofluorescence

13. Americas Bullous pemphigoid Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Bullous pemphigoid Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Bullous pemphigoid Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
  • 16.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie
  • 2. Alexion Pharmaceuticals
  • 3. Almirall
  • 4. Amgen
  • 5. AstraZeneca
  • 6. Biogen
  • 7. Bristol-Myers Squibb
  • 8. Dermira
  • 9. Eli Lilly and Company
  • 10. F. Hoffmann-La Roche
  • 11. GlaxoSmithKline
  • 12. Horizon Therapeutics
  • 13. Johnson & Johnson
  • 14. Merck & Co.
  • 15. Novartis
  • 16. Pfizer
  • 17. Regeneron Pharmaceuticals
  • 18. Sanofi
  • 19. Takeda Pharmaceutical Company
  • 20. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. BULLOUS PEMPHIGOID MARKET RESEARCH PROCESS
  • FIGURE 2. BULLOUS PEMPHIGOID MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. BULLOUS PEMPHIGOID MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. BULLOUS PEMPHIGOID MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BULLOUS PEMPHIGOID MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BULLOUS PEMPHIGOID MARKET DYNAMICS
  • TABLE 7. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SYSTEMIC CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY FIRST-LINE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY MAINTENANCE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SECOND-LINE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY MILD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DIRECT IMMUNOFLUORESCENCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ELISA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY INDIRECT IMMUNOFLUORESCENCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 132. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 136. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 138. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 139. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 142. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 143. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 146. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 147. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 149. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 150. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 151. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 152. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 153. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 154. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 157. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 158. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 160. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 161. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 163. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 164. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 165. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 168. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 169. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 171. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 172. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 173. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 174. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 175. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 176. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 179. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 180. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 182. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 183. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 185. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 186. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 187. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 190. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 191. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 193. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 194. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 196. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 198. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 200. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 201. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 202. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 204. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 205. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 206. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 207. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 208. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 209. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 211. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 212. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 213. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 215. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 216. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 218. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 219. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 220. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 223. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 224. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 226. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 227. TAIWAN BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 228. TAIWAN BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 229. TAIWAN BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 230. TAIWAN BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 231. TAIWAN BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. TAIWAN BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 233. TAIWAN BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 234. TAIWAN BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 235. TAIWAN BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. TAIWAN BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 237. TAIWAN BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 238. THAILAND BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 239. THAILAND BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 240. THAILAND BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 241. THAILAND BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 242. THAILAND BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 243. THAILAND BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 244. THAILAND BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 245. THAILAND BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 246. THAILAND BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. THAILAND BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 248. THAILAND BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 249. VIETNAM BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 250. VIETNAM BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 251. VIETNAM BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 252. VIETNAM BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 253. VIETNAM BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 254. VIETNAM BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 255. VIETNAM BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 256. VIETNAM BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 257. VIETNAM BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. VIETNAM BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 259. VIETNAM BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 272. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 273. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 274. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 275. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 276. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 277. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 278. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 279. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 280. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 282. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 283. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 284. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 285. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 286. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 287. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 288. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 289. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 290. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 291. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 292. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 293. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 294. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 295. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 296. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 297. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 298. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 299. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 300. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 301. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 302. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 304. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 305. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 306. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 307. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 308. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 309. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 310. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 311. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 312. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 313. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 315. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 316. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 317. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 318. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 319. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 320. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 321. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 322. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 323. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 324. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 325. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 326. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 327. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 328. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 329. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 330. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 331. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 332. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 333. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 334. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 335. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 336. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 337. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 338. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 339. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 340. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 341. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 342. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 343. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 344. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 345. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 346. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 347. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 348. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 349. NETHERLANDS BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 350. NETHERLANDS BULLOUS PEMPHIGOID MARKET SI